BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, with lead programs in metastatic breast cancer and personalized off-the-shelf immunotherapies.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, under FDA Fast Track Designation, with positive survival data reported in prior studies.

• Pipeline includes Bria-OTS™ and Bria-OTS+™ for personalized immunotherapies, and a soluble CD80 protein therapeutic.

• Recent collaborations include Memorial Sloan Kettering and Receptor.AI to accelerate development and expand into small-molecule oncology.

Financial performance and metrics

• For the year ended July 31, 2025: operating loss of $27.2M, net loss of $26.3M, and $13.1M in total assets as of October 31, 2025.

• As adjusted for the offering, cash and cash equivalents would increase to $25.4M, and total assets to $35.8M.

• Weighted average shares outstanding for the year: 423,114; net loss per share: $(62.19).

Use of proceeds and capital allocation

• Estimated net proceeds of $22.71M (assuming full sale at $8.95 per unit), with no minimum offering amount.

• Proceeds intended for working capital, general corporate purposes, and advancement of business objectives, with management retaining broad discretion over allocation.